Sorry, you need to enable JavaScript to visit this website.

Main navigation

  • For US Healthcare Professionals Only
  • Important Safety Information
  • Prescribing Information
  • Patient Site
  • Request Samples For US Healthcare Professionals Only
  • Request Samples
Zenpep Delayed-Release Capsules
  • About EPI
  • Dosing
  • Efficacy
  • Safety
  • MOA
  • FAQs
  • Coverage and Support
  • EPI Due to CF
    • About EPI in CF
    • Dosing
    • Safety
    • Coverage and Support
  • About EPI
  • Dosing
  • Efficacy
  • Safety
  • MOA
  • FAQs
  • Coverage and Support
  • EPI Due to CF
    • About EPI in CF
    • Dosing
    • Safety
    • Coverage and Support

Site Map

  • Home
  • About EPI
  • Dosing
  • Efficacy
  • Safety
  • MOA
  • FAQs
  • Coverage and Support
  • EPI due to CF
    • About EPI in CF
    • Dosing
    • Safety
    • Coverage and Support

INDICATIONS AND IMPORTANT
SAFETY INFORMATION

MORE LESS

INDICATIONS AND USAGE

ZENPEP® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Fibrosing Colonopathy

  • Fibrosing colonopathy is a rare serious adverse reaction initially described in association with use of high-dose pancreatic enzyme products, usually with use over a prolonged period of time and most commonly reported in pediatric patients with cystic fibrosis.
  • Exercise caution when doses of ZENPEP exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day or 4,000 lipase units/g fat ingested/day).

Irritation of the Oral Mucosa

  • Crushing or chewing ZENPEP capsules or mixing the capsule contents in foods having a pH greater than 4.5 can cause irritation of the oral mucosa. Do not crush or chew capsules or capsule contents.

Hyperuricemia

  • Pancreatic enzyme products contain purines that may increase blood uric acid levels. High dosages have been associated with hyperuricosuria and hyperuricemia.

Risk of Viral Transmission

  • There is theoretical risk for transmission of viral disease. However, no cases of transmission of an infectious illness associated with the use of porcine pancreatic extracts have been reported.

Hypersensitivity Reactions

  • Severe hypersensitivity reactions including anaphylaxis, asthma, hives, and pruritus have been reported with pancreatic enzyme products.
  • Monitor patients with a known hypersensitivity reaction to proteins of porcine origin for hypersensitivity reactions during treatment with ZENPEP.

Adverse Reactions

  • The most common adverse reactions (≥6% of patients treated with ZENPEP) were headache, contusion, cough, and early satiety.

Additional Important Safety Information

  • Do not substitute other pancreatic enzyme products for ZENPEP.
Please see the full Prescribing Information for ZENPEP.
Nestlé Health Science

All trademarks are owned by Société des Produits Nestlé S.A.,
Vevey, Switzerland, or used with permission. ©2025 Nestlé.
ZP-PM-USA-0081 03/25

The product information provided in this site is intended for
residents of the United States.

  • Prescribing Information
  • Patient Medication Guide
  • Terms of Use
  • your-privacy Your Privacy Choices
  • Contact Us
  • Privacy Policy
  • Site Map
Zenpep Delayed-Release Capsules

Please verify that you are a US Healthcare Professional.
This site is intended for US Healthcare Professionals.

I AM A US-LICENSED HEALTHCARE
PROFESSIONAL
I AM NOT A US-LICENSED HEALTHCARE PROFESSIONAL